GB0521276D0 - Medical uses and therapies based upon the action of azurocidin on IGFBP-1 - Google Patents

Medical uses and therapies based upon the action of azurocidin on IGFBP-1

Info

Publication number
GB0521276D0
GB0521276D0 GBGB0521276.6A GB0521276A GB0521276D0 GB 0521276 D0 GB0521276 D0 GB 0521276D0 GB 0521276 A GB0521276 A GB 0521276A GB 0521276 D0 GB0521276 D0 GB 0521276D0
Authority
GB
United Kingdom
Prior art keywords
azurocidin
igfbp
action
medical uses
therapies based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0521276.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HALL KERSTIN E
LEWITT MOIRA S
Original Assignee
HALL KERSTIN E
LEWITT MOIRA S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HALL KERSTIN E, LEWITT MOIRA S filed Critical HALL KERSTIN E
Priority to GBGB0521276.6A priority Critical patent/GB0521276D0/en
Publication of GB0521276D0 publication Critical patent/GB0521276D0/en
Priority to US12/091,004 priority patent/US20100129344A1/en
Priority to PCT/GB2006/003885 priority patent/WO2007045873A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0521276.6A 2005-10-19 2005-10-19 Medical uses and therapies based upon the action of azurocidin on IGFBP-1 Ceased GB0521276D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0521276.6A GB0521276D0 (en) 2005-10-19 2005-10-19 Medical uses and therapies based upon the action of azurocidin on IGFBP-1
US12/091,004 US20100129344A1 (en) 2005-10-19 2006-10-19 Medical uses and therapies based upon the action of azurocidin on igfbp-1
PCT/GB2006/003885 WO2007045873A2 (en) 2005-10-19 2006-10-19 Medical uses and therapies based upon the action of azurocidin on igfbp-1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0521276.6A GB0521276D0 (en) 2005-10-19 2005-10-19 Medical uses and therapies based upon the action of azurocidin on IGFBP-1

Publications (1)

Publication Number Publication Date
GB0521276D0 true GB0521276D0 (en) 2005-11-30

Family

ID=35458292

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0521276.6A Ceased GB0521276D0 (en) 2005-10-19 2005-10-19 Medical uses and therapies based upon the action of azurocidin on IGFBP-1

Country Status (3)

Country Link
US (1) US20100129344A1 (en)
GB (1) GB0521276D0 (en)
WO (1) WO2007045873A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016161D0 (en) 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
GB201102108D0 (en) 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607916A (en) * 1989-07-05 1997-03-04 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
WO1991000907A1 (en) * 1989-07-05 1991-01-24 Emory University Monocyte chemotactic proteins and related peptides
AU703963B2 (en) * 1994-04-21 1999-04-01 Leukotech A/S Heparin-binding protein for the treatment of sepsis and processes for its preparation
CA2214799A1 (en) * 1995-03-09 1996-09-19 Novo Nordisk A/S A protein-lipid conjugate, consisting of heparin binding protein (hbp) and a ceramide analogue, and its pharmaceutical use in treatment of conditions involving stress injury to cells
US5837247A (en) * 1995-06-16 1998-11-17 United States Of America As Represented By The Public Health Service National Institutes Of Health Chemotactic agents for t-cells
DE19757250A1 (en) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein and its use

Also Published As

Publication number Publication date
US20100129344A1 (en) 2010-05-27
WO2007045873A3 (en) 2007-08-09
WO2007045873A2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
EP1912650B8 (en) Use of flibanserin in the treatment of obesity
EP1968649A4 (en) Protein nanoparticles and the use of the same
ZA200800464B (en) Peptides for use in the treatment of obesity
AP3071A (en) Ganaxolone formulations and methods for the makingand use thereof
HK1119070A1 (en) Use of trans-clomiphene in the manufacture of medicines
GB2425380B (en) Computing with both lock-step and free-step processor modes
EP1874800A4 (en) Diagnostic and therapeutic agents
IL198010A0 (en) Phenylpropionamide compounds and the use thereof
HRP20130622T1 (en) Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
HK1141312A1 (en) Cdca1 peptide and pharmaceutical agent comprising the same cdca1
GB0516069D0 (en) Pharmaceutical and use thereof
EP1962635A4 (en) Stress-reducer for shoulder and the use thereof
TWI368509B (en) Antituberculous therapeutic drugs and kit containing the same
EP2094711B8 (en) Structural mimetics of proline-rich peptides and the pharmaceutical use thereof
EP1841581A4 (en) Composites and methods for the manufacture and use thereof
EP1942563A4 (en) Connection member and harness connection body using the connection member
IL189252A0 (en) Dihydroxyanthraquinones and their use
HUP0500701A2 (en) Conductive-polymer electrode from multicomponent system and the use thereof
EP1856973A4 (en) Organ function maintaining and ameliorating solution
GB0521276D0 (en) Medical uses and therapies based upon the action of azurocidin on IGFBP-1
GB0512726D0 (en) Multiple sclerosis therapy and diagnosis
GB0508840D0 (en) Determining the age of skin bruises
GB0521353D0 (en) Medical uses and therapies based upon the action of azurocidin on IGFBP-1
EP1767210A4 (en) The medical use of paeoniflorin
JP2006045555A5 (en) Polyester and polyester molded body comprising the same

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)